Logo Logo
Hilfe
Hilfe
Switch Language to English

Bérouti, Marleen ORCID logoORCID: https://orcid.org/0009-0009-6081-5408; Wagner, Mirko; Greulich, Wilhelm ORCID logoORCID: https://orcid.org/0009-0003-9946-4226; Piseddu, Ignazio ORCID logoORCID: https://orcid.org/0000-0001-8331-9778; Gärtig, Jan; Hansbauer, Larissa; Müller-Hermes, Christoph; Heiss, Matthias ORCID logoORCID: https://orcid.org/0000-0002-6770-9511; Pichler, Alexander ORCID logoORCID: https://orcid.org/0000-0002-9842-0155; Tölke, Annika J. ORCID logoORCID: https://orcid.org/0000-0002-3139-3412; Witte, Gregor; Hopfner, Karl-Peter ORCID logoORCID: https://orcid.org/0000-0002-4528-8357; Anz, David; Sattler, Michael ORCID logoORCID: https://orcid.org/0000-0002-1594-0527; Carell, Thomas ORCID logoORCID: https://orcid.org/0000-0001-7898-2831 und Hornung, Veit ORCID logoORCID: https://orcid.org/0000-0002-4150-194X (2025): Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement. In: Cell [Forthcoming]

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Highlights

• The non-immunogenicity of Ψ-RNA results from poor processing by lysosomal nucleases

• RNase T2 and PLDs fail to generate TLR7 and TLR8 ligands from Ψ-modified RNA

• Ψ and Ψ-RNA poorly engage distinct ligand-binding pockets of TLR8 and TLR7

• m1Ψ evades nuclease cleavage but could activate TLR8 if released from RNA

Summary

Recognition of exogenous RNA by Toll-like receptors (TLRs) is central to pathogen defense. Using two distinct binding pockets, TLR7 and TLR8 recognize RNA degradation products generated by endolysosomal nucleases. RNA modifications present in endogenous RNA prevent TLR activation; notably, pseudouridine-containing RNA lacks immunostimulatory activity. Indeed, this property has been critical to the successful implementation of mRNA technology for medical purposes. However, the molecular mechanism for this immune evasion has remained elusive. Here, we report that RNase T2 and PLD exonucleases do not adequately process pseudouridine-containing RNA to generate TLR-agonistic ligands. As a second safety mechanism, TLR8 neglects pseudouridine as a ligand for its first binding pocket and TLR7 neglects pseudouridine-containing RNA as a ligand for its second pocket. Interestingly, the medically used N1-methylpseudouridine also evades RNase T2, PLD3, and PLD4 processing but is able to directly activate TLR8. Taken together, our findings provide a molecular basis for self-avoidance by RNA-sensing TLRs.

Dokument bearbeiten Dokument bearbeiten